Metformin and its sulphonamide derivative simultaneously potentiateanti-cholinesterase activity of donepezil and inhibit beta-amyloid aggregation

References

• Sahoo AK, Dandapat J, Dash UC, et al. Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer’s disease. J Ethnopharmacol 2018;215:42–73.
   PubMed Web of Science ®Google Scholar
• Amatsubo T, Yanagisawa D, Morikawa S, et al. Amyloid imaging using high-field magnetic resonance. Magn Reson Med Sci 2010;9:95–9.
   PubMed Web of Science ®Google Scholar
• Hersi M, Irvine B, Gupta P, et al. Risk factors associated with the onset and progression of Alzheimer’s disease: a systematic review of the evidence. Neurotoxicology 2017;61:143–87.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Huang NQ, Yan F, et al. Diabetes mellitus and Alzheimer’s disease: GSK-3β as a potential link. Behav Brain Res 2018;339:57–65.
   PubMed Web of Science ®Google Scholar
• Kumar D, Ganeshpurkar A, Kumar D, et al. Secretase inhibitors for the treatment of Alzheimer’s disease: long road ahead. Eur J Med Chem 2018;148:436–52.
   PubMed Web of Science ®Google Scholar
• Kuca K, Soukup O, Maresova P, et al. Current approaches against Alzheimer’s disease in clinical trials. J Braz Chem Soc 2016;27:641–9.
   Web of Science ®Google Scholar
• Kumar K, Kumar A, Keegan RM, et al. Recent advances in the neurobiology and neuropharmacology of Alzheimer’s disease. Biomed Pharmacother 2018;98:297–307.
   PubMed Web of Science ®Google Scholar
• Tonelli DM, Catto DM, Tasso DB, et al. Multitarget therapeutic leads for Alzheimer’s disease. Quinolizidinyl derivatives of bi- and tri-cyclic systems as dual inhibitors of cholinesterases and Aβ aggregation. ChemMedChem 2015;10:1040–53.
   PubMed Web of Science ®Google Scholar
• Folch J, Ettcheto M, Petrov D, et al. Review of the advances in treatment for Alzheimer disease: strategies for combating β-amyloid protein. Neurol 2017;33:47–58.
   Web of Science ®Google Scholar
• Korábečný J, Nepovimová E, Cikánková T, et al. Newly developed drugs for Alzheimer’s disease in relation to energy metabolism, cholinergic and monoaminergic neurotransmission. Neuroscience 2018;370:191–206.
   PubMed Web of Science ®Google Scholar
• Cheignon C, Tomas M, Bonnefont-Rousselot D, et al. Oxidative stress and the amyloid beta peptide in Alzheimer’s disease. Redox Biol 2018;14:450–64.
   PubMed Web of Science ®Google Scholar
• Villa V, Thellung S, Bajetto A, et al. Novel celecoxib analogues inhibit glial production of prostaglandin E2, nitric oxide, and oxygen radicals reverting the neuroinflammatory responses induced by misfolded prion protein fragment 90-231 or lipopolysaccharide. Pharmacol Res 2016;113:500–14.
   PubMed Web of Science ®Google Scholar
• Villa V, Thellung S, Corsaro A, et al. Celecoxib inhibits prion protein 90-231-mediated Pro-inflammatory responses in microglial cells. Mol Neurobiol 2016;53:57–72.
   PubMed Web of Science ®Google Scholar
• Markowicz-Piasecka M, Huttunen KM, Mateusiak Ł, et al. Is metformin a perfect drug? Updates in pharmacokinetics and pharmacodynamics. Curr Pharm Des 2017;23:2532–50.
   PubMed Web of Science ®Google Scholar
• Kalyanaraman B, Cheng G, Hardy M, et al. Modified metformin as a more potent anticancer drug: mitochondrial inhibition, redox signaling, antiproliferative effects and future EPR studies. Cell Biochem Biophys 2017;75:311–17.
   PubMed Web of Science ®Google Scholar
• Markowicz-Piasecka M, Sikora J, Szydłowska A, et al. Metformin – a future therapy for neurodegenerative diseases: theme: drug discovery, development and delivery in Alzheimer’s disease Guest Editor: Davide Brambilla. Pharm Res 2017;34:2614.
   PubMed Web of Science ®Google Scholar
• Guo M, Mi J, Jiang QM, et al. Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus. Clin Exp Pharmacol Physiol 2014;41:650–6.
   PubMed Web of Science ®Google Scholar
• Herath PM, Cherbuin N, Eramudugolla R, et al. The effect of diabetes medication on cognitive function: evidence from the PATH through life study. Biomed Res Int 2016;2016:1.
   Web of Science ®Google Scholar
• Scarpello JH, Howlett HC. Metformin therapy and clinical uses. Diabetes Vasc Dis Res. 2008;5:157–67.
   PubMed Web of Science ®Google Scholar
• Azadeh E-H, Asadbegi M, Salehi I, et al. Neuroprotective role of antidiabetic drug metformin against amyloid beta peptide-induced neuronal loss in hippocampal CA1 pyramidal neurons in rats fed high fat diet. J Chem Pharm Sci 2016;9:3460–5.
   Google Scholar
• Patrone C, Eriksson O, Lindholm D. Diabetes drugs and neurological disorders: new views and therapeutic possibilities. Lancet Diabetes Endocrinol 2014;2:256–62.
   PubMed Web of Science ®Google Scholar
• Wang J, Gallagher D, Devito LM, et al. Metformin activates an atypical PKC-CBP pathway to promote neurogenesis and enhance spatial memory formation. Cell Stem Cell 2012;11:23–35.
   PubMed Web of Science ®Google Scholar
• Bhutada P, Mundhada Y, Bansod K, et al. Protection of cholinergic and antioxidant system contributes to the effect of berberine ameliorating memory dysfunction in rat model of streptozotocin-induced diabetes. Behav Brain Res 2011;220:30–41.
   PubMed Web of Science ®Google Scholar
• Saliu JA, Oboh G, Omojokun OS, et al. Effect of dietary supplementation of Padauk (Pterocarpus soyauxii) leaf on high fat diet/streptozotocin induced diabetes in rats’ brain and platelets. Biomed. Pharmacother 2016;84:1194–201.
   PubMed Web of Science ®Google Scholar
• Markowicz-Piasecka M, Sikora J, Mateusiak A, et al. Metformin and its sulfenamide prodrugs inhibit human cholinesterase activity. Oxid Med Cell Longev 2017;2017:1.
   Web of Science ®Google Scholar
• Huttunen KM, Leppänen J, Laine K, et al. Convenient microwave-assisted synthesis of lipophilic sulfenamide prodrugs of metformin. Eur J Pharm Sci 2013;49:624–8.
   PubMed Web of Science ®Google Scholar
• Rautio J, Vernerová M, Aufderhaar I, et al. Glutathione-S-transferase selective release of metformin from its sulfonamide prodrug. Bioorganic Med Chem Lett 2014;24:5034–6.
   PubMed Web of Science ®Google Scholar
• Kajbaf F, De Broe ME, Lalau J-D. Therapeutic concentrations of metformin: a systematic review. Clin Pharmacokinet 2016;55:439–59.
   PubMed Web of Science ®Google Scholar
• Markowicz-Piasecka M, Huttunen KM, Mikiciuk-Olasik E, Sikora J. Biocompatible sulfenamide and sulfonamide derivatives of metformin can exert beneficial effects on plasma haemostasis. Chem Biol Interact 2018;280:15.
   PubMed Web of Science ®Google Scholar
• Kuźma Ł, Wysokińska H, Sikora J, et al. Taxodione and extracts from Salvia austriaca roots as human cholinesterase inhibitors. Phyther Res 2016;30:234–42.
   PubMed Web of Science ®Google Scholar
• Chou T-C, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994;86:1517–24.
   PubMed Web of Science ®Google Scholar
• Chou T-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621–81.
   PubMed Web of Science ®Google Scholar
• Walsh R, Rockwood K, Martin E, Darvesh S. Synergistic inhibition of butyrylcholinesterase by galantamine and citalopram. Biochin Biophys Acta 2011;1810:1230–5.
   PubMed Web of Science ®Google Scholar
• Imramovsky A, Stepankova S, Vanco J, et al. Acetylcholinesterase-inhibiting activity of salicylanilide N-alkylcarbamates and their molecular docking. Molecules 2012;17:10142–58.
   PubMed Web of Science ®Google Scholar
• Mezeiova E, Spilovska K, Nepovimova E, et al. Profiling donepezil template into multipotent hybrids with antioxidant properties. J Enzyme Inhib Med Chem 2018;33:583–606.
   PubMed Web of Science ®Google Scholar
• García-Ayllón M-S. Revisiting the role of acetylcholinesterase in Alzheimer’s disease: cross-talk with P-tau and β-amyloid. Front Mol Neurosci 2011;4:1–9.
   PubMed Web of Science ®Google Scholar
• Arendt T, Brückner MK. Perisomatic sprouts immunoreactive for nerve growth factor receptor and neurofibrillary degeneration affect different neuronal populations in the basal nucleus in patients with Alzheimer’s disease. Neurosci Lett 1992;148:63–6.
   PubMed Web of Science ®Google Scholar
• Grossberg GT. Cholinesterase inhibitors for the treatment of Alzheimer's disease: getting on and staying on. Curr Ther Res Clin Exp 2003;64:216–35.
   PubMed Web of Science ®Google Scholar
• Giacobini E, Spiegel R, Enz A, et al. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer’s disease by rivastigmine: correlation with cognitive benefit. J Neural Transm (Vienna) 2002;109:1053–65.
   PubMed Web of Science ®Google Scholar
• Greig NH, Utsuki T, Ingram DK, et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer-amyloid peptide in rodent. Proc Natl Acad Sci 2005;102:17213–8.
   PubMed Web of Science ®Google Scholar
• Nordberg A, Ballard C, Bullock R, et al. A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer’s disease. Prim Care Companion CNS Disord 2013;15:12r01412.
   Google Scholar
• Sridhar GR, Rao AA, Srinivas K, et al. Butyrylcholinesterase in metabolic syndrome. Med Hypotheses 2010;75:648–51.
   PubMed Web of Science ®Google Scholar
• Abbott CA, MacKness MI, Kumar S, et al. Relationship between serum butyrylcholinesterase activity, hypertriglyceridemia and insulin sensitivity in diabetes mellitus. Clin Sci 1993;85:77–81.
   PubMed Web of Science ®Google Scholar
• Iwasaki T, Yoneda M, Nakajima A, et al. Serum butyrylcholinesterase is strongly associated with adiposity, the serum lipid profile and insulin resistance. Intern Med 2007;46:1633–9.
   PubMed Web of Science ®Google Scholar
• Shahmohamadnejad S, Vaisi-Raygani A, Shakiba Y, et al. Association between butyrylcholinesterase activity and phenotypes, paraoxonase192 rs662 gene polymorphism and their enzymatic activity with severity of rheumatoid arthritis: correlation with systemic inflammatory markers and oxidative stress, preliminary. Clin Biochem 2015;48:63–9.
   PubMed Web of Science ®Google Scholar
• Khan H, Marya, Amin S, et al. Flavonoids as acetylcholinesterase inhibitors: current therapeutic standing and future prospects. Biomed Pharmacother 2018;101:860–70.
   PubMed Web of Science ®Google Scholar
• Wang J, Wang ZM, Li XM, et al. Synthesis and evaluation of multi-target-directed ligands for the treatment of Alzheimer’s disease based on the fusion of donepezil and melatonin. Bioorganic Med Chem 2016;24:4324–38.
   PubMed Web of Science ®Google Scholar
• Bajda M, Więckowska A, Hebda M, et al. Structure-based search for new inhibitors of cholinesterases. Int J Mol Sci 2013;14:5608–32.
   PubMed Web of Science ®Google Scholar
• Mak S, Luk WWK, Cui W, et al. Synergistic inhibition on acetylcholinesterase by the combination of berberine and palmatine originally isolated from Chinese medicinal herbs. J Mol Neurosci 2014;53:511–16.
   PubMed Web of Science ®Google Scholar
• Johnson GVW. Tau phosphorylation in neuronal cell function and dysfunction. J Cell Sci 2004;117:5721–9.
   PubMed Web of Science ®Google Scholar
• Sun X, Bromley‐Brits K, Song W. Regulation of beta-site APP cleaving enzyme 1 gene expression and its role in Alzheimer’s disease. J Neurochem 2012;120:62–70.
   PubMed Web of Science ®Google Scholar
• Agis-Torres A, Sollhuber M, Fernandez M, et al. Multi-target-directed ligands and other therapeutic strategies in the search of a real solution for Alzheimer’s disease. Curr Neuropharmacol 2014;12:2–36.
   PubMed Web of Science ®Google Scholar
• Akrami H, Mirjalili BF, Khoobi M, et al. Indolinone-based acetylcholinesterase inhibitors: synthesis, biological activity and molecular modeling. Eur J Med Chem 2014;84:375–81.
   PubMed Web of Science ®Google Scholar
• Hettich MM, Matthes F, Ryan DP, et al. The anti-diabetic drug metformin reduces BACE1 protein level by interfering with the MID1 complex. PLoS One 2014;9:e102420.
   PubMed Web of Science ®Google Scholar
• Li J, Deng J, Sheng W, et al. Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant mice . Pharmacol Biochem Behav 2012;101:564–74.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhou K, Wang R, et al. Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer’s amyloid peptides via up-regulating BACE1 transcription. Proc Natl Acad Sci 2009;106:3907–12.
   PubMed Web of Science ®Google Scholar
• Imfeld P, Bodmer M, Jick SS, et al. Metformin, other antidiabetic drugs, and risk of Alzheimer’s disease: a population-based case-control study. J Am Geriatr Soc 2012;60:916–21.
   PubMed Web of Science ®Google Scholar